SESSION TITLE: Fellow Case Report Poster - Lung Cancer
SESSION TYPE: Affiliate Case Report Poster
PRESENTED ON: Tuesday, October 25, 2016 at 01:30 PM - 02:30 PM
INTRODUCTION: Recent approval of programmed cell death-1 inhibitors for non-small cell lung cancer (NSCLC) has rapidly led to their widespread use. Pneumonitis has been recognized as a rare(1-3%) life-threatening adverse event1; however clinical & radiological manifestations remain yet to be described. We describe a case with development of nivolumab-induced pneumonitis in 12 weeks of initiation.